AstraZeneca PLC (LON:AZN) Given Average Rating of “Moderate Buy” by Brokerages

Shares of AstraZeneca PLC (LON:AZN) have received a consensus rating of “Moderate Buy” from the nine analysts that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is £104.12 ($133.03).

A number of research analysts have recently issued reports on AZN shares. Berenberg Bank reiterated a “buy” rating and set a £150 ($191.64) target price on shares of AstraZeneca in a research report on Monday, September 2nd. JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a £140 ($178.87) price objective on shares of AstraZeneca in a report on Friday, November 22nd. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a research note on Thursday, November 7th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a £110 ($140.54) price target on shares of AstraZeneca in a research note on Tuesday, September 3rd.

Insider Transactions at AstraZeneca

In related news, insider Tony Mok purchased 1,500 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The stock was purchased at an average price of £126.80 ($162.00) per share, with a total value of £190,200 ($243,004.98). Also, insider Michel Demare acquired 2,000 shares of the stock in a transaction on Friday, September 13th. The shares were bought at an average cost of GBX 118 ($1.51) per share, for a total transaction of £2,360 ($3,015.20). Over the last three months, insiders have acquired 23,500 shares of company stock valued at $223,316,000. Corporate insiders own 0.04% of the company’s stock.

AstraZeneca Stock Performance

Shares of AZN stock opened at £105.12 ($134.30) on Wednesday. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 84.97. AstraZeneca has a 12-month low of GBX 9,461 ($120.88) and a 12-month high of £133.88 ($171.05). The business’s 50 day moving average is £110.42 and its two-hundred day moving average is £119.40. The company has a market capitalization of £162.94 billion, a P/E ratio of 3,337.14, a P/E/G ratio of 0.86 and a beta of 0.17.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.